Elementis has sold its pharmaceutical business, lifted first-half profits by 16% and launched a buyback, as it sharpens its focus on personal care and coatings.

Elementis (LSE:ELM), the specialty chemicals group best known for its rheology modifiers and hectorite clay, is several months into a portfolio simplification that management hopes will make the Business easier to value. Its half-year results, published on 30 July, combined solid organic growth with a higher Margin and confirmation that the sale of its pharmaceutical Manufacturing business had been completed. The company has since been buying back its own shares, with regular transaction notices filed through the autumn.

Margins move higher

Revenue for the first six months of 2026 was $318.2m, up from $290.8m a year earlier and representing organic growth of about 4.7% at constant currency. Adjusted operating profit rose by 16% to $73.2m, lifting the adjusted Operating Margin to 23.0% from 21.6%. Adjusted Diluted Earnings per Share increased by almost 29% to 8.5 cents, and the Interim Dividend was raised by around 15% to 1.5 cents.

Chief executive Luc van Ravenstein said Revenue was up 5% on an organic basis, profits were up 16%, margins were improving and net Debt was close to the company's target of one times earnings. Net debt stood at $163.8m, equivalent to about 1.1 times EBITDA.

Two divisions, two growth stories

The personal care division generated revenue of $109.2m, up about 3% organically, and an adjusted operating profit of $41.6m, giving a margin above 38%. The company pointed to new hectorite-based products for skincare and suncare and to a contribution from the Alchemy acquisition. The larger coatings division delivered revenue of $209.0m, up about 5.6% organically, with a margin of around 20.7%. Elementis said its energy-related products performed well and it launched six new products across architectural and construction markets.

Operational measures also improved. The proportion of orders delivered on time and in full rose to 88% from 83% at the end of 2025, and the group delivered net cost savings of $0.5m in the half while remaining on track for a $4m full-year target.

Pharma exit and buyback

The biggest strategic step was the disposal of the pharmaceutical manufacturing business to Associated British Foods, which completed on 2 June. The deal valued the operation at an Enterprise value of €34.3m and generated net proceeds of around $36m, along with a book gain of $13m. Management said the sale leaves Elementis as a pure-play specialty chemicals business. It is using the proceeds to fund a share buyback of about $35m, which has been running since the summer.

What to watch

For the full year, Elementis said it remained confident of delivering a performance in line with expectations. Company-compiled market expectations at the time pointed to adjusted operating profit of about $132.5m, within a range of roughly $129m to $137m. The board flagged that it is monitoring geopolitical risks in the Middle East, which can affect energy markets, raw material costs and Demand for some of its coatings products.

There has been little new company-specific news since the interim results beyond the buyback, so the next significant catalyst is likely to be the full-year trading update in early 2027. In the meantime, the shares will remain sensitive to wider sentiment towards chemicals stocks, which has been tested by soft industrial demand across Europe and by volatile energy prices.